A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme by Malynn, Barbara A. & Ma, Averil
977
COMMENTARY
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 206 No. 5  977-980
www.jem.org/cgi/doi/10.1084/jem.20090765
Lymphomas are the fifth most common 
of human malignancies; the chance of 
developing  lymphoma  during  one’s 
lifetime is 2%. The vast majority of 
lymphomas are B cell lineage derived 
and can be characterized as Hodgkin or 
non-Hodgkin lymphomas. Both classes 
can  be  further  subtyped  based  upon 
their  biological  properties,  including 
differentiation stage, clinical pathology, 
and the response to therapeutic treat-
ment (1). Many important clues to lym-
phoma pathogeneses have come from 
cytogenetic  and  genetic  analyses  of   
somatic mutations (e.g., translocations 
and gene deletions), as well as gene   
expression  profiling  (2).  Mutations   
in  NF-B  and  JAK/STAT  signaling 
proteins cause defects in B cell survival 
and  proliferation  and  contribute  to 
lymphomagenesis  (3).  On  page  981 
of this issue, Schmitz et al. examine 
whether  mutations  in  the  TNFAIP3 
gene contribute to cellular transforma-
tion in human B cell lymphomas (4). 
Their data show that a large number of 
Hodgkin lymphomas and primary me-
diastinal lymphomas contain bi-allelic 
mutations of TNFAIP3 that result in 
loss of the A20 protein. Other recent 
studies  have  also  found  TNFAIP3 
mutations in marginal zone B cell lym-
phomas (5, 6). These and future studies 
of ubiquitin modifiers may reveal new 
directions for the discovery of antican-
cer therapies.
A20 keeps the peace
A20 was first identified in 1990 as a 
TNF-induced molecule that restricts 
TNF-triggered NF-B signaling (7). Its 
widespread expression and potent anti-
inflammatory functions were unveiled 
when A20-deficient mice (A20
/) were 
found to exhibit severe spontaneous 
multiorgan inflammation, cachexia, and 
premature death (8). Epistasis experi-
ments revealed that genetic deletion of 
TNF or TNF receptor 1 (TNFR1) in 
A20-deficient mice did not rescue the 
mice from premature death, demonstrat-
ing that A20 regulates proinflammatory 
signals in addition to TNF (9). We now 
know that A20 also restricts NF-B sig-
naling in response to stimulation of the 
TLR and NOD pathways (9, 10). A20 
regulates innate immune homeostasis in-
dependently of adaptive immune cells, as 
A20
/ RAG-1
/ mice lacking mature 
T and B cells develop severe spontane-
ous inflammation and perinatal death (8). 
The defects caused by A20 deficiency 
were ameliorated in mice that also lacked 
the TLR adaptor protein MyD88 and in 
mice treated with antibiotics to deplete 
commensal intestinal bacteria (11). These 
results highlight the potentially proinflam-
matory nature of homeostatic MyD88-
dependent signals, as well as A20’s critical 
role in restricting these signals and main-
taining immune homeostasis.
The mechanics of A20 action
The biochemical mechanisms by which 
A20 restricts NF-B signaling are unique 
and complex. The A20 protein contains 
an ovarian tumor (OTU) domain at the 
N terminus and seven zinc finger (ZF) 
domains at the C terminus. The OTU 
domain functions as a deubiquitinating 
(DUB) enzyme to remove activating 
lysine-63 (K63)–linked polyubiquitin 
chains from receptor-interacting protein 
(RIP),  an  essential  mediator  of  the 
proximal TNFR1 signaling complex. 
The A20 ZF domain functions as an E3 
ubiquitin  ligase,  adding  K48-linked 
polyubiquitin chains to RIP1 and tar-
geting the protein for proteasomal deg-
radation. Hence, A20 appears to be a 
dual function enzyme that adds and sub-
tracts  ubiquitin  moieties  to  deactivate 
and degrade RIP (12). In addition to 
regulating TNF-induced RIP ubiquity-
lation, A20 restricts TLR-induced NF-
B signals by deubiquitylating the E3 
ligase TRAF6 (9, 11). A20 also damp-
ens NOD1- and NOD2-induced NF-
B  signals  by  deubiquitylating  RIP2, 
possibly  preventing  it  from  recruiting 
IKK  to  the  signaling  complex  (10). 
Hence, like other DUBs and E3 ligases, 
A20 regulates the ubiquitylation of mul-
tiple protein targets.
Many B cell cancers are characterized in part by the dysregulation of the NF-
B signaling pathway. A new study identifies somatic mutations in TNFAIP3, 
the gene encoding the NF-B inhibitor A20, in Hodgkin lymphomas and 
primary mediastinal lymphomas. These data reveal the role of A20 as a tumor 
suppressor protein.
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A large number of Hodgkin 
lymphomas and primary  
mediastinal lymphomas  
contain bi-allelic mutations 
of TNFAIP3 that result in 
loss of the A20 protein
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and  perhaps  A20,  thereby  inducing 
constitutive NF-B signaling (21, 22). 
Although the precise biochemical rela-
tionships  between  EBV  proteins  and 
A20  are  unclear,  the  genetic  epistasis 
unveiled by Schmitz et al. may pro-
vide  intriguing  clues  about  B  cell 
lymphomagenesis.
Most of the TNFAIP3 mutations 
found  in  Hodgkin  and  mediastinal 
lymphomas were nonsense or frame-
shift mutations that prevented produc-
tion  of  full-length  A20  protein  (4). 
Combined  with  the  observation  that 
both alleles were mutated in the tumor 
samples,  the  common  pathogenetic 
mechanism of A20 in lymphoma de-
velopment  is  likely  a  loss  of  protein 
function.  Mutations  were  found 
throughout the coding sequence, and 
some  mutations  had  the  potential  to 
encode partial proteins. As partial A20 
proteins containing only the N-termi-
nal OTU domain have been shown to 
retain deubiquitinating activity (9), the 
E3 ligase activity of A20 may be criti-
cal for its tumor suppressor function. It 
is also intriguing that six of the seven 
replacement  mutations  observed  in 
both cHL and PMBL were clustered in 
the terminal zinc finger domains ZF6 
and  ZF7,  which  are  thought  to  be 
largely dispensable for A20’s E3 ligase 
activity (12). This suggests that subtle 
reductions  in  E3  ligase  activity  that 
may result from these mutations can be 
tumorigenic. Alternatively, previously 
unappreciated  functions  of  A20  may 
be harbored in these domains.
Autoimmunity–cancer link?
Several  chronic  autoimmune  diseases 
are associated with increased risk of de-
veloping lymphoma (23). Recent ge-
netic studies in humans revealed several 
polymorphisms in the TNFAIP3 gene 
region as risk alleles for the develop-
ment of systemic lupus erythematosus 
is possible that A20 may also regulate B 
cell homeostasis and activation.
A20’s cancer connection
A20-deficient  cells  exhibit  prolonged 
NF-B signaling in response to a vari-
ety  of  innate  immune  ligands,  and 
chronic NF-B activation has been as-
sociated with lymphomas (3). Genetic 
analyses  have  identified  deletions  in 
chromosome 6q that are associated with 
Hodgkin lymphoma and other subtypes 
of  B  cell  lymphomas  (e.g.,  marginal 
zone lymphomas, MALT lymphomas, 
and diffuse large B cell lymphomas). As 
the TNFAIP3 gene is located at 6q23, 
Schmitz  et  al.  (4)  proposed  that  A20 
might be pathogenetic in these human 
cancers. The authors focused their mo-
lecular analysis on primary mediastinal 
B cell lymphomas (PMBLs) and classi-
cal Hodgkin lymphoma (cHL), as the 
transcriptional profiles of these tumors 
are similar.
Remarkably,  they  found  that  bi-
  allelic somatic mutations in TNFAIP3 
were found in 16/36 cHLs and 5/14 
PMBLs. Reconstitution of A20 expres-
sion induced cell death in A20 mutant 
lymphoma cell lines, but not in A20-
sufficient lymphoma cells. These find-
ings provide direct evidence that A20 is 
a tumor suppressor gene that is mutated 
with  high  frequency  in  these  human 
lymphomas.
Schmitz el al. also make the intrigu-
ing observation that A20 mutations are 
found  in  14/20  (70%)  EBV-negative 
cHL compared with only 2/16 (12.5%) 
EBV-positive  lymphomas,  suggesting 
that  EBV-dependent  transformation 
perturbs  B  cell  signaling  in  a  fashion 
similar to A20 deletion. Indeed, earlier 
studies  suggested  that  the  EBV  latent 
membrane protein 1 may mimic CD40 
signaling  by  interacting  with  TRAFs, 
A20  also  binds  to  the  E3  ligases 
TRAF1,  TRAF2,  TRAF6,  Itch,  and 
RNF11, as well as to the adaptor pro-
tein TXBP1 and the ubiquitin sensor 
ABIN-1 (13–17). These proteins col-
laborate with A20 to regulate NF-B 
and  MAP  kinase  signaling  cascades 
and  TNF-induced  cell  death.  How 
this ubiquitin-dependent, multiprotein 
complex functions, how it targets spe-
cific  signaling  cascades,  and  whether 
distinct  subsets  of  this  complex  pref-
erentially  regulate  different  signaling 
proteins are among the questions that 
remain to be answered.
A20 also inhibits programmed cell 
death (PCD) (8, 18). Increased suscep-
tibility to PCD in A20-deficient cells 
is not caused by deficiencies in the ex-
pression  of  NF-B–induced  survival 
proteins, as these cells have exaggerated 
NF-B  signaling  and  normal  expres-
sion  of  NF-B  survival  proteins,  yet 
are more susceptible to TNF-induced 
PCD (8). Because limiting the lifespan 
of activated immune cells helps restrain 
inflammatory responses, the antiinflam-
matory and antiapoptotic functions of 
A20 impart dichotomous regulatory in-
fluences on immune homeostasis.
A20 in lymphocytes
Although most studies investigating the 
function of A20 have focused on innate 
immune  signals,  A20  is  constitutively 
expressed and can be further induced in 
both T and B cells (7, 8, 19). However, 
the protein’s function in lymphocytes is 
poorly understood. In T cells, the mu-
cosal-associated lymphoid tumor–asso-
ciated  (MALT1)  protein  cleaves  A20 
during TCR activation, which is one 
mechanism  by  which  MALT1  pro-
motes TCR-induced NF-B activation 
(20). BCR stimulation of B lymphoma 
cell  lines  also  leads  to  A20  cleavage. 
However, the physiological role of A20 
and its cleavage in T and B cells is un-
clear. Mature B cells are regulated by 
NF-B signals triggered by the BCR, 
BAFF, and CD40. Because these sig-
naling cascades may share some of the 
same  ubiquitin-dependent  proximate 
signaling molecules used by TNF and 
TLR ligands (e.g., TRAF2, TRAF6), it 
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(SLE),  rheumatoid  arthritis,  psoriasis, 
and celiac disease (24–29). While only 
one  missense  coding  allele  has  been 
identified thus far (in SLE), the well-
established antiinflammatory functions of 
A20 in mice suggest that hypomorphic 
function  or  expression  of  A20  may 
contribute  to  the  pathophysiology  of 
these human conditions (24). Collec-
tively, these findings suggest that subtle 
germline  TNFAIP3  hypomorphisms 
may predispose individuals to chronic 
autoimmune  diseases,  whereas  gross 
A20 deficiencies occurring somatically 
may contribute to lymphoma. In this 
context, it will be revealing to further 
analyze  TNFAIP3  polymorphisms  in 
autoimmune  patients  and  determine 
whether there is an association between 
certain polymorphisms and lymphoma 
risk. Considered from another perspec-
tive,  the  severe  pathogenetic  conse-
quences of A20 deficiency may mean 
that  deletional  germline  mutations  of 
A20 are unlikely to be detected in the 
human population. These studies along 
with the results presented by Schmitz   
et al. (4) and others (5, 6) suggest that A20 
may be a prevalent suppressor of both 
autoimmune disease and lymphoma in 
human  patients,  thereby  providing  a 
critical molecular link between chronic 
inflammation and cancer.
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ing mutations in known oncogenes or 
tumor suppressor genes. In this context, 
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monitor  these  animals  for  spontaneous 
tumor development. Lineage-specific 
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these studies. In this regard, it will be 
particularly interesting to determine how 
A20 intrinsically regulates B cell func-
tions by analyzing mice lacking A20 
specifically in B cells.
Many questions also remain unre-
solved regarding the role of A20 in pro-
A20 may be a prevalent sup-
pressor of both autoimmune 
disease and lymphoma in 
human patients980 TUMOR SUPPRESSION BY A20 | Malynn and Ma
2004. Deubiquitination and ubiquitin ligase 
domains  of  A20  downregulate  NF-kappaB 
signalling. Nature. 430:694–699. 
  13.  Song, H.Y., M. Rothe, and D.V. Goeddel. 
1996.  The  tumor  necrosis  factor-induc-
ible zinc finger protein A20 interacts with 
TRAF1/TRAF2  and  inhibits  NF-kap-
paB activation. Proc. Natl. Acad. Sci. USA. 
93:6721–6725. 
  14.  Heyninck,  K.,  D.  De  Valck,  W.  Vanden 
Berghe,  W.  Van  Criekinge,  R.  Contreras, 
W.  Fiers,  G.  Haegeman,  and  R.  Beyaert. 
1999.  The  zinc  finger  protein  A20  inhib-
its  TNF-induced  NF-kappaB-dependent 
gene  expression  by  interfering  with  an 
RIP-  or  TRAF2-mediated  transactivation 
signal and directly binds to a novel NF-kap-
paB-inhibiting  protein  ABIN.  J.  Cell  Biol. 
145:1471–1482. 
  15.  De  Valck  D.,  D.Y.  Jin,  K.  Heyninck,  M. 
Van de Craen, R. Contreras, W. Fiers, K.T. 
Jeang, and R. Beyaert. 1999. The zinc finger 
protein A20 interacts with a novel anti-apop-
totic protein which is cleaved by specific cas-
pases. Oncogene. 18:4182–4190. 
  16.  Shembade, N., N.S. Harhaj, K. Parvatiyar, 
N.G. Copeland, N.A. Jenkins, L.E. Matesic, 
and E.W. Harhaj. 2008. The E3 ligase Itch 
negatively  regulates  inflammatory  signal-
ing  pathways  by  controlling  the  function 
of the ubiquitin-editing enzyme A20. Nat. 
Immunol. 9:254–262. 
  17.  Shembade, N., K. Parvatiyar, N.S. Harhaj, 
and E.W. Harhaj. 2009. The ubiquitin-edit-
ing enzyme A20 requires RNF11 to down-
regulate  NF-kappaB  signalling.  EMBO  J. 
28:513–522. 
  18.  Opipari, A.W. Jr., H.M. Hu, R. Yabkowitz, 
and V.M. Dixit. 1992. The A20 zinc fin-
ger  protein  protects  cells  from  tumor  ne-
crosis  factor  cytotoxicity.  J.  Biol.  Chem. 
267:12424–12427.
  19.  Sarma,  V.,  Z.  Lin,  L.  Clark,  B.M.  Rust, 
M.  Tewari,  R.J.  Noelle,  and  V.M.  Dixit. 
1995. Activation of the B-cell surface recep-
tor CD40 induces A20, a novel zinc finger 
protein that inhibits apoptosis. J. Biol. Chem. 
270:12343–12346. 
  20.  Coornaert, B., M. Baens, K. Heyninck, T. 
Bekaert, M. Haegman, J. Staal, L. Sun, Z.J. 
Chen, P. Marynen, and R. Beyaert. 2008. 
T cell antigen receptor stimulation induces 
MALT1  paracaspase-mediated  cleavage  of 
the NF-kappaB inhibitor A20. Nat. Immunol. 
9:263–271. 
  21.  Uchida, J., T. Yasui, Y. Takaoka-Shichijo, 
M. Muraoka, W. Kulwichit, N. Raab-Traub, 
and H. Kikutani. 1999. Mimicry of CD40 
signals by Epstein-Barr virus LMP1 in B lym-
phocyte responses. Science. 286:300–303. 
  22.  Fries,  K.L.,  W.E.  Miller,  and  N.  Raab-
Traub. 1999. The A20 protein interacts with 
the Epstein-Barr virus latent membrane pro-
tein 1 (LMP1) and alters the LMP1/TRAF1/
TRADD complex. Virology. 264:159–166. 
  23.  Goldin,  L.R.,  and  O.  Landgren.  2009. 
Autoimmunity and lymphomagenesis. Int. J. 
Cancer. 124:1497–1502. 
  24.  Musone,  S.L.,  K.E.  Taylor,  T.T.  Lu,  J. 
Nititham, R.C. Ferreira, W. Ortmann, N. 
Shifrin, M.A. Petri, M.I. Kamboh, S. Manzi, 
et al. 2008. Multiple polymorphisms in the 
TNFAIP3 region are independently associ-
ated with systemic lupus erythematosus. Nat. 
Genet. 40:1062–1064. 
  25.  Graham, R.R., C. Cotsapas, L. Davies, R. 
Hackett, C.J. Lessard, J.M. Leon, N.P. Burtt, 
C.  Guiducci,  M.  Parkin,  C.  Gates,  et  al. 
2008.  Genetic  variants  near  TNFAIP3  on 
6q23 are associated with systemic lupus ery-
thematosus. Nat. Genet. 40:1059–1061. 
  26.  Plenge, R.M., C. Cotsapas, L. Davies, A.L. 
Price, P.I. de Bakker, J. Maller, I. Pe’er, N.P. 
Burtt,  B.  Blumenstiel,  M.  DeFelice,  et  al. 
2007. Two independent alleles at 6q23 asso-
ciated with risk of rheumatoid arthritis. Nat. 
Genet. 39:1477–1482. 
  27.  Thomson W, A. Barton, X. Ke, S. Eyre, A. 
Hinks, J. Bowes, R. Donn, D. Symmons, 
S.  Hider,  I.N.  Bruce;  Wellcome  Trust 
Case  Control  Consortium,  A.G.  Wilson, 
I. Marinou, A. Morgan, P. Emery; YEAR 
Consortium, A. Carter, S. Steer, L. Hocking, 
D.M.  Reid,  P.  Wordsworth,  P.  Harrison, 
D.  Strachan,  and  J.  Worthington.  2007. 
Rheumatoid  arthritis  association  at  6q23. 
Nat. Genet. 39:1431–1433. 
  28.  Nair, R.P., K.C. Duffin, C. Helms, J. Ding, 
P.E. Stuart, D. Goldgar, J.E. Gudjonsson, Y. 
Li, T. Tejasvi, B.J. Feng, et al; Collaborative 
Association  Study  of  Psoriasis.  2009. 
Genome-wide  scan  reveals  association  of 
psoriasis with IL-23 and NF-kappaB path-
ways. Nat. Genet. 41:199–204. 
  29.  Trynka G, A. Zhernakova, J. Romanos, L. 
Franke,  K.  Hunt,  G.  Turner,  M.  Platteel, 
A.W. Ryan, C. de Kovel, D. Barisani, M.T. 
Bardella, R. McManus, D.A. Van Heel, and 
C. Wijmenga. 2009. Coeliac disease associ-
ated  risk  variants  in  TNFAIP3  and  REL 
implicate altered NF-kappaB signaling. Gut. 
doi: 10.1136/gut.2008.169052.